Jefferies Financial Group Reiterates Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by investment analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday, Digital Look reports. They presently have a £175 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s price objective would indicate a potential upside of 47.95% from the stock’s previous close.

Several other research firms have also recently weighed in on AZN. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a report on Wednesday, September 2nd. Berenberg Bank restated a “buy” rating and set a £160 target price on shares of AstraZeneca in a report on Thursday, September 3rd. Finally, Citigroup raised their price target on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of £151.14.

AstraZeneca Stock Performance

AstraZeneca stock opened at £118.28 on Wednesday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The firm has a market cap of £183.44 billion, a P/E ratio of 17.71, a P/E/G ratio of 0.86 and a beta of 0.20. AstraZeneca has a 1-year low of £107.84 and a 1-year high of £157.32. The firm has a 50-day moving average of £124.79 and a 200-day moving average of £136.10.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.